(NTLA) Intellia Therapeutics - Ratings and Ratios

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage biotechnology company pioneering the development of genome editing therapies aimed at treating severe genetic and acquired diseases. The companys pipeline emphasizes in vivo gene editing, with its lead program NTLA-2001 currently in Phase 1 clinical trials for transthyretin amyloidosis, a progressive and debilitating condition affecting multiple organ systems. NTLA-2002, another in vivo candidate, is under investigation in a Phase 1/2 study for hereditary angioedema, a rare and potentially life-threatening disorder. Beyond its in vivo efforts, Intellia is advancing ex vivo programs centered on engineered cell therapies, targeting cancers and autoimmune diseases through next-generation approaches.

Intellia has established a network of strategic collaborations to expand its therapeutic reach. These include partnerships with AvenCell Therapeutics to develop allogeneic universal CAR-T cell therapies, Kyverna Therapeutics for an allogeneic CD19 CAR-T cell therapy targeting B cell-mediated autoimmune diseases, ONK Therapeutics for engineered NK cell therapies in oncology, and ReCode Therapeutics to explore novel genomic medicines for cystic fibrosis. These alliances underscore Intellias commitment to leveraging its proprietary CRISPR-based genome editing platform to address a broad spectrum of unmet medical needs. Founded in 2014, the company operates from its headquarters in Cambridge, Massachusetts, a hub for biotechnological innovation.